Key result
A 19-year-old male patient with primary mediastinal large B-cell lymphoma experienced refractory disease despite multiple lines of therapy and died of sudden respiratory arrest in the seventh month.
Case Report (n=1)
No
This case highlights the aggressive nature and potential for early fatal complications in primary mediastinal large B-cell lymphoma despite multimodal therapy.
Highlights mediastinal mass evaluation in adolescents; extends sparse case data but leaves optimal therapy open.
Primary mediastinal large B-cell lymphoma is a rare tumour. Patients present with dyspnea, cough, dysphagia and superior vena cava syndrome. Thus, most patients are diagnosed early in stages 1-2. We reported a 19-year-old male patient diagnosed with primary mediastinal large B-cell lymphoma.
No takes yet. Share an insight, caveat, or question.
Candar et al. (2022) conducted a case report in Primary Mediastinal Large B-Cell Lymphoma (n=1). R-CHOP, R-DHAP, radiotherapy, and nivolumab plus brentuximab was evaluated on Clinical outcome. A 19-year-old male patient with primary mediastinal large B-cell lymphoma experienced refractory disease despite multiple lines of therapy and died of sudden respiratory arrest in the seventh month.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: